Abstract 416P
Background
Head and neck cancer is one of the most common malignancies in India, with the highest incidence worldwide. Our aim was to study head and neck sarcomas- tumor types, their treatment strategies, recurrence patterns and survival in patients treated in a tertiary centre in the densely populated Northern India.
Methods
This is a retrospective study of a prospectively maintained database. Patients treated between January 2011- June 2016 at the centre were included. Surgical treatment was wide excision (aim was to get disease free margins within the restrictions of the region). Chemotherapy was mainly doxorubicin-based with drugs like cisplatin, ifosfamide, etoposide, vincristine and cyclophosfamide added as per the histology. Radiotherapy was given as part of the curative treatment in Ewing’s sarcoma. Adjuvant radiation therapy was given in close/involved margins or locally advanced disease in other histologies. Patients with distant or locally advanced disease underwent multimodal management.
Results
The study included 29 cases. Histologies were varied, with the most common type being osteosarcoma, followed by chondrosarcoma. Ewing’s sarcoma, pleomorphic sarcoma and spindle cell sarcoma were the other common types. Most common site of involvement was mandible. Surgery was done in 68.9% (n = 20). High grade disease was seen in 22 patients (75.9%). Margins were clear in 17 patients (80.9%); close margins were documented in 4 patients (19%). Locoregional and distant recurrences occurred in 15% (n = 3) & 10% (n = 2), respectively. Factors affecting the risk of recurrence are high grade, close margins and locally advanced disease. However there is no influence of size, grade or margin status on survival. Median survival was 33 months. The 3 year disease free survival was 52% (95% CI- 0.44-0.83).
Conclusions
Head and neck sarcoma is a rare heterogeneous group in one of the commonest sites of malignancy in India. Apart from appropriate identification of the cases, the better chance of survival is provided by an expert unit with multidisciplinary management, and chance of surgical salvage in case of recurrence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract